Nutrition

Egrifta approved for HIV-associated abdominal lipodystrophy

Merck and EMD Serono announced that the FDA has approved Egrifta (tesamorelin for injection), a growth hormone releasing factor (GRF) analog, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.